For the gastrin-releasing peptide receptor’s (GRPR) imaging, which is overexpressed in several types of cancer, such as prostate cancer, breast cancer, colorectal and pancreatic cancer, and lung and ovarian cancer, several gallium-68-based radiopharmaceuticals were designed [175], specifically [68Ga]-Ga-BBN-RGD for breast cancer [180], [68Ga]-NOTA-DUPA-RM26 for prostate cancer, and [68Ga]-Ga-NOTA-Aca-BBN for glioma imaging [181]. This evidence concerns the gene GRPR and central nervous system cancer.